Italia - italiano - Ministero della Salute

emra food snc di e.bramante -

Italia - italiano - Ministero della Salute

emra food snc di e.bramante -

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - soluzione iniettabile per sottocutaneo - tocilizumabum 162 mg, polysorbatum 80, arginini hydrochloridum, methioninum, histidinum, histidini hydrochloridum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 0.9 ml. - l'artrite reumatoide, arterite a cellule giganti, polyartikuläre l'artrite idiopatica giovanile sistemica giovanile idiopatische artrite - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - soluzione iniettabile in penna pre-riempita per sottocutaneo - tocilizumabum 162 mg, polysorbatum 80, arginini hydrochloridum, methioninum, histidinum, histidini hydrochloridum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 0.9 ml. - l'artrite reumatoide, arterite a cellule giganti, polyartikuläre l'artrite idiopatica giovanile sistemica artrite idiopatica giovanile - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosoppressori - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - concentrato per soluzione per infusione - tocilizumabum 80 mg, polysorbatum 80, saccharum, dinatrii phosphas dodecahydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 1.76 mg. - l'artrite reumatoide. sistemica artrite idiopatica giovanile. polyartikuläre l'artrite idiopatica giovanile. zytokinfreisetzungssyndrom. - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - concentrato per soluzione per infusione - tocilizumabum 200 mg, polysorbatum 80, saccharum, dinatrii phosphas dodecahydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 4.43 mg. - l'artrite reumatoide. sistemica artrite idiopatica giovanile. polyartikuläre l'artrite idiopatica giovanile. zytokinfreisetzungssyndrom. - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - concentrato per soluzione per infusione - tocilizumabum 400 mg, polysorbatum 80, saccharum, dinatrii phosphas dodecahydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 20 ml corresp. natrium 8.84 mg. - l'artrite reumatoide. sistemica artrite idiopatica giovanile. polyartikuläre l'artrite idiopatica giovanile. zytokinfreisetzungssyndrom. - biotechnologika

Italia - italiano - Ministero della Salute

emra food snc di e.bramante -